期刊论文Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo …复制

DOI:复制

文献链接:复制

其他信息:

求助补充材料，谢谢

JH Krystal, JM Kane, CU Correll, DP Walling, M Leoni…
The Lancet, 2022
thelancet.com
Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator in development for the treatment of schizophrenia. We aimed to evaluate the safety and tolerability of multiple ascending doses of emraclidine in patients with schizophrenia. Methods We conducted a two-part, randomised, phase 1b trial in the USA. Eligible participants were aged 18–50 years (part A) or 18–55 years (part B) with a primary diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental …